Literature DB >> 15468032

Joint range of motion limitations in children and young adults with spinal muscular atrophy.

Hui Yi Wang1, Yun Huei Ju, Shu Mei Chen, Sing Kai Lo, Yuh Jyh Jong.   

Abstract

OBJECTIVES: To elicit descriptive data about limited joint range of motion (ROM) in subjects with type II or III spinal muscular atrophy (SMA) and to examine the relation between the number of motions with limited range and both age and functional ability.
DESIGN: Descriptive cross-sectional study.
SETTING: Neurologic pediatric outpatient clinic at a hospital in Taiwan. PARTICIPANTS: Twenty-seven subjects with SMA type II (mean age, 9.8+/-6.5y) and 17 with SMA type III (mean age, 12.2+/-8.7y). Intervention Measurement with transparent goniometers of joint ROM bilaterally of the shoulder, elbow, wrist, hip, knee, and ankle. MAIN OUTCOME MEASURES: The proportion of participants with each ROM limitation compared with all participants with the same SMA type, age distribution of the participants with each ROM limitation, mean range loss of each motion limitation, and the contracture index (risk index of joint contracture).
RESULTS: Eighty-nine percent of the participants with SMA type II experienced knee extension limitation. Approximately 50% of the participants with both types of SMA had ankle dorsiflexion limitation. The motions of knee and hip extension and ankle dorsiflexion also had a relatively high contracture index. The number of motions with limited range positively correlated ( P <.001) with age and upper-extremity functional grade (the higher the functional grade, the poorer the functional ability) for SMA type II.
CONCLUSIONS: We found varying degrees of joint ROM limitation. Certain motions were noted to be high risks for the development of contractures. This risk was higher mostly in younger children.

Entities:  

Mesh:

Year:  2004        PMID: 15468032     DOI: 10.1016/j.apmr.2004.01.043

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  8 in total

Review 1.  Spinal Muscular Atrophy.

Authors:  Stephen J Kolb; John T Kissel
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

Review 2.  Spinal muscular atrophy: diagnosis and management in a new therapeutic era.

Authors:  W David Arnold; Darine Kassar; John T Kissel
Journal:  Muscle Nerve       Date:  2014-12-16       Impact factor: 3.217

3.  Proteasome inhibition preserves longitudinal growth of denervated muscle and prevents neonatal neuromuscular contractures.

Authors:  Sia Nikolaou; Alyssa Aw Cramer; Liangjun Hu; Qingnian Goh; Douglas P Millay; Roger Cornwall
Journal:  JCI Insight       Date:  2019-12-05

Review 4.  Proximal spinal muscular atrophy: current orthopedic perspective.

Authors:  Gerrit Haaker; Albert Fujak
Journal:  Appl Clin Genet       Date:  2013-11-14

5.  Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.

Authors:  Xing Chen; Juliane Siebourg-Polster; Detlef Wolf; Christian Czech; Ulrike Bonati; Dirk Fischer; Omar Khwaja; Martin Strahm
Journal:  PLoS One       Date:  2017-01-25       Impact factor: 3.240

6.  New Approaches to Exciting Exergame-Experiences for People with Motor Function Impairments.

Authors:  Martina Eckert; Ignacio Gómez-Martinho; Juan Meneses; José-Fernán Martínez
Journal:  Sensors (Basel)       Date:  2017-02-12       Impact factor: 3.576

7.  Reliability of four tests to assess body posture and the range of selected movements in individuals with spinal muscular atrophy.

Authors:  Agnieszka Stępień; Maria Jędrzejowska; Katarzyna Guzek; Witold Rekowski; Jolanta Stępowska
Journal:  BMC Musculoskelet Disord       Date:  2019-02-07       Impact factor: 2.362

8.  Cervical rotation, chest deformity and pelvic obliquity in patients with spinal muscular atrophy.

Authors:  Agnieszka Stępień; Łucja Mazurkiewicz; Katarzyna Maślanko; Witold Rekowski; Maria Jędrzejowska
Journal:  BMC Musculoskelet Disord       Date:  2020-11-07       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.